anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One use of datalogger's is for gathering physiological conditional data about a person. A person can carry a datalogger and any associated sensors whilst they are in motion. The data recorded by the datalogger can then be uploaded to a third party system for analysis. Datalogger's that record physiological information have a variety of uses. For example, they can be used for medical purposes to monitor a patient's response to a course of treatment, or to monitor background factors about a person's lifestyle that may allow a doctor to advise on healthy living, and for sports purposes, to monitor an athlete's performance. 
     Energy consumption is a significant issue in the design of datalogger's. It is desirable for a datalogger to be small and light, with a self-contained energy source such as a battery, but also to operate for as long as possible. This document describes means to prolong the life of the battery attached to both sensory devices and datalogger's alike. Also detailed are scalable bandwidth mechanisms to present the time series data in a manner such that the system may maintain a level of control, which may be predetermined and controlled by the system administrator, of brief or verbose data transfer dependant upon the functionality required. A level of sensory device category criticality is also included in to the system such that graceful degradation of the system might be achieved whilst supporting a level of criticality of the data prescribed by the system designer.
Risk Summary   
Available data from case reports, case series, and observational studies on fluocinolone acetonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids may be associated with an increased risk of low birthweight infants. Advise pregnant women to use DERMA-SMOOTHE/FS Body Oil on the smallest area of skin and for the shortest duration possible.

Corticosteroids can cause fetal malformations in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids cause fetal malformations after dermal application in laboratory animals.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
120 patients undergoing elective thoracoscopic surgery were randomly divided into ESPB group (E group, n=30), TPVB group (T group, n=30), ESPB combine with TPVB group (ET group, n=30), ICNB group (I group, n=30). Patients in ESPB group underwent erector spinal block under ultrasound after anesthesia induction; Patients in TPVB group received thoracic paravertebral nerve block after anesthesia induction; Patients in ESPB group combined with TPVB group received thoracic paravertebral nerve block combined with erectoralis muscle block after anesthesia induction; Patients in INB group received intraoperative intercostal nerve block by the operator. All groups of patients received postoperative controlled intravenous analgesia (PCIA). Visual analogue scale (VAS) was used to evaluate the degree of pain 1h (T1), 24h (T2) and 48h (T3) after surgery. The mean arterial pressure (MAP), heart rate at T1-T3 were recorded, as well as the number of effective analgesic pump compression, the amount of sufentanil and the number of relief analgesia within 48h after surgery. The occurrence of postoperative adverse reactions such as nausea, vomiting, dizziness, retention time of thoracic drainage tube, postoperative hospital stay and postoperative pulmonary complications (pneumonia, atelectasis, pleural effusion, respiratory failure, etc.) were recorded.
Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
The TriAD study is a multi-center, multi-country Prospective Pragmatic Cohort study assessing the effectiveness, feasibility, acceptability, and cost-effectiveness of implementing the Xpert MTB/XDR (Xpert XDR; Cepheid) assay for rapid triage-and-treatment with short, all- oral drug resistant tuberculosis (DR-TB) treatment. The proposed study aims to screen approximately 4800 GeneXpert MTB/RIF or Ultra MTB-positive (irrespective of rifampicin resistance status) patients from 9 study sites in South Africa, Nigeria and Ethiopia to enrol 880 rifampicin resistant (RR) and 400 isoniazid mono-resistant (HR) patients over a period of 12-18 months. The Xpert XDR assay, a rapid genotypic test, will be implemented as a reflex test to detect resistance to isoniazid, fluoroquinolones and second-line injectable agents to provide rapid genotypic susceptibility testing for DR-TB detection. Patients that test positive for Mycobacterium tuberculosis with rifampicin resistance will be enrolled in Cohort 1 (n=880). Patients that test positive for Mycobacterium tuberculosis that are rifampicin susceptible with isoniazid mono-resistance will be enrolled in Cohort 2 (n=400). Results from the Xpert XDR assay will be used to guide selection of appropriate, evidence-based, all-oral DR-TB treatment regimens of shortest possible duration. The tuberculosis molecular bacterial load assay (TB-MBLA) will be used as an adjunct to provide bacillary load monitoring over the course of treatment to assess real-time treatment response. Operational research will provide information about the feasibility, acceptability and cost-effectiveness to inform policies and guidelines for programmatic implementation of the triage-and-treat model.
Methods for the treatment of neuroinflammation or neurotoxicity are provided. For example, a method is provided for preventing neuroinflammation or neurotoxicity in a subject comprising administering to a subject an mGluR5 agonist. Also provided is a method of preventing neuroinflammation or neurotoxicity in a subject, wherein the subject has a central nervous system injury, comprising administering to the subject an mGluR5 agonist. Methods can further comprise preventing neuroinflammation or neurotoxicity in a subject, wherein the subject has or is suspected of having a neurodegenerative disease. The provided methods are useful for treating acute or chronic injury or disorder. For example, provided are methods of treating a subject having a nervous system disease or injury, comprising administering to the subject having the nervous system disease or injury an mGluR5 agonist.
This is a multicenter, cross-over, randomized, controlled and double blind study. 24 patients will be included between November 2015 and November 2017.

During each session of speech and language treatment, aphasics will receive a weak 2 milli amperes (electric) current delivered by a tDCs device for 20 minutes. The stimulation will be either active or placebo. Each stage of the cross over will last three weeks. Patients will be administered the usual number of SLT sessions, no particular therapy being imposed. To evaluate the long-time effects of the therapy, three follow-up measures will be proposed.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to novel para- -terphenyl compounds of the formula (I)   or their pharmaceutically acceptable salts or hydrates that elicit immunosuppressive and antiallergic effect, in part, they elicit IgE-selective producing suppressive activity, to method of their synthesis and pharmaceutical compositions based on thereof. In compounds of the formula (I) X means -O-, -CH 2 -, -NR 14  where R 14  means hydrogen atom, optionally substituted lower alkyl, optionally substituted alkenyl or acetyl, or -S(O) p  where p means a whole number from 0 to 2; Y means hydrogen atom, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl; Y can mean optionally substituted lower alkoxy-group if X means -CH 2 - and can mean optionally substituted lower alkoxycarbonyl, optionally substituted lower alkylsulfonyl or optionally substituted arylsulfonyl if X means -O- or -NR 14 ; R 1 -R 13  can mean different values indicated in the invention claim, for example, R 1  and R 2 ; R 1  and R 4 ; R 6  and R 7 ; R 8  and R 9 , R 11  and -X-Y or R 13  and -X-Y taken in common can form 5- or 6-membered ring that can comprise one or more atoms taken among O, S or NR 15 . Methods of synthesis of compounds of the formula (I) involve interaction of different phenyl fragments corresponding to fragments of the formula (I). Pharmaceutical compositions comprise compounds of the formula (I), its pharmaceutically acceptable salt or hydrate and pharmaceutically acceptable vehicle. EFFECT: improved methods of synthesis, valuable medicinal properties of compounds. 15 cl, 4 dwg, 334 tbl
Cigarette smoking is associated with various health problems, particularly certain forms of cancer and early death (Centers for Disease Control and Prevention, 1997). More recently, smoking has become a global problem among youth and it is imperative that research puts an emphasis on prevention and intervention particularly in this age group (World Health Organization, 2009). Over the past few years, research has shown that internet-based interventions are more cost effective, cater to individuals who are unable/unwilling to attend weekly treatment sessions with a therapist, and are promising in terms of improving attrition rates, a major problem with most treatment trials. Moreover, internet-based interventions use technology often utilized to attract youth (interactive games, animation, video clips etc.) and thus may reach and engage a wider range of individuals than traditional face-to-face interventions. ACT is an empirically-based intervention that uses acceptance and mindfulness strategies and has been shown to increase psychological flexibility. The aim of the present study is to investigate the usefulness and effectiveness of an Acceptance and Commitment Therapy (ACT) internet-based smoking cessation intervention program for college, high school and vocational school student smokers. Findings are expected to show that a digitalized program designed to engage youth in smoking cessation can result in quitting smoking and has a high applicability potential especially among the hard-to-reach population of youth.
Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
Secondary or repeated revascularization refers to any repeated coronary intervention following an index coronary revascularization procedure, and represents a wide proportion of patients received in catheterization laboratories. These patients have an increased complexity and worse outcomes than patients without previous revascularization. Clinical investigation has focused in lesion-specific treatments when a single previous revascularization fails, but there is paucity of patient-level information including complex patients with multiple revascularizations. Other gaps in evidence addressed by this study are the absence of a a prognosis-oriented classification of previously revascularized patients and a clinical meaningful definition of revascularization failure. The registry as well intends to provide insights on how secondary revascularization decisions are taken and long term prognosis after secondary revascularization.

The registry of secondary revascularization (in Spanish: Registro multicéntrico de reVAscularización SECundaria, REVASEC) is a multicenter, prospective, observational cohort study that incudes consecutive patients with at least one previous coronary revascularization undergoing a clinically indicated diagnostic coronary angiography, in different Spanish hospitals. The aims are describing the incidence, clinical profile, therapeutic management and prognosis of these patients.
BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases.
PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation.
RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response.
INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.
In the heart, genetic or acquired mishandling of diastolic [Ca2+] by ryanodine receptor type 2 (RyR2) overactivity correlates with risks of arrhythmia and sudden cardiac death. Strategies to avoid these risks include decrease of Ca2+ release by drugs modulating RyR2 activity or increase in Ca2+ uptake by drugs modulating SR Ca2+ ATPase (SERCA2a) activity. Here, we combine these strategies by developing experimental compounds that act simultaneously on both processes. Our screening efforts identified the new 1,4-benzothiazepine derivative GM1869 as a promising compound. Consequently, we comparatively studied the effects of the known RyR2 modulators Dantrolene and S36 together with GM1869 on RyR2 and SERCA2a activity in cardiomyocytes from wild type and arrhythmia-susceptible RyR2R2474S/+ mice by confocal live-cell imaging. All drugs reduced RyR2-mediated Ca2+ spark frequency but only GM1869 accelerated SERCA2a-mediated decay of Ca2+ transients in murine and human cardiomyocytes. Our data indicate that S36 and GM1869 are more suitable than dantrolene to directly modulate RyR2 activity, especially in RyR2R2474S/+ mice. Remarkably, GM1869 may represent a new dual-acting lead compound for maintenance of diastolic [Ca2+].
Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
Dental moulding properties &c. of hydrocolloids, e.g agar-agar, are improved by adding a slightly alkaline aqueous dispersion of an oxide or hydroxide of an amphoteric metal, e.g. tin, zinc, manganese or aluminium, and a finely-divided, water-insoluble inorganic filler, e.g. calcium sulphate, precipitated calcium carbonate, or magnesium carbonate.  A borate, e.g. calcium metaborate may also be included. The hydroxide may be formed by precipitation from an acid salt solution such as tin sulphate or chloride by adding an alkaline compound of an alkali metal, and may be peptized by potassium hydrate.
Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS \>=8 and/or BPE/BPO questionnaire \>=3 with a PSA \>=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
PURPOSE:To prepare a health drink which can taken with little feeling of the bitter taste, by adding a masking agent and a sweetener to an aqueous solution containing a drug component and a bitter component. CONSTITUTION:Cyclodextrin (a substance composed of about 6-8 glucose redidues bonded together to form a ring), an edible surface active agent (e.g. sugar ester), etc. are used as the masking agent for the bitter component. The above masking agent, a sweetener, a flavor, etc. are added to an aqueous solution containing a drug component and a bitter component (e.g. tannic acid, bitter glycoside, etc.) (e.g. an aqueous extract of Fomes japonicus) to obtain a health drink agreeable to drink, and composed of about 20wt% of sweetener, about 0.3-2wt% of extract, about 0.01-0.5wt% of masking agent, about 0.01- 0.4wt% of flavor and remainig part of water, wherein the bitter component is clathrated with the masking agent.
The recommended dosage for women 18 years of age and older for uncomplicated urinary tract infection (acute cystitis) is one sachet of fosfomycin tromethamine granules for oral solution. Fosfomycin tromethamine granules for oral solution may be taken with or without food.

Fosfomycin tromethamine granules for oral solution should not be taken in its dry form. Always mix fosfomycin tromethamine granules for oral solution with water before ingesting. (See PREPARATION section.)

PREPARATION

Fosfomycin tromethamine granules for oral solution should be taken orally. Pour the entire contents of a single-dose sachet of fosfomycin tromethamine granules for oral solution into 3 to 4 ounces of water (1/2 cup) and stir to dissolve. Do not use hot water. Fosfomycin tromethamine granules for oral solution should be taken immediately after dissolving in water.
This is a prospective, multicenter, randomized sham-controlled trial. Patients with uncontrolled hypertension (office BP ≥150/90 and \<180/110mmHg, and average SBP ≥135mmHg by 24-hour ambulatory BP monitoring (ABPM), after taking ≥2 antihypertensive drugs with stable dose for ≥ 4 weeks) were screened after informed consent. All eligible patients first entered a lead-in period for ≥4 weeks of standardized medication (Nifedipine + hydrochlorothiazide), and those continued to meet definition of uncontrolled hypertension were randomized 2:1 to RDN group and sham control group (renal artery angiography only). All continued with the 2-drug regimen and were evaluated at 7, 30, 60, 90 and 180 days post procedure. Both patients and site investigators who evaluate the patients were blinded to treatment assignment. The primary endpoint is office SBP change from baseline at 6 months post procedure. Secondary endpoints include changes from baseline of office DBP. 24-hour ABPM at 6 months post procedure and safety events.
The invention relates to a traditional Chinese medicine composition for treating pulmonary fibrosis diseases, which is prepared from the following raw material medicines in parts by weight: 28-31 parts of radix rehmanniae, 29-32 parts of centella asiatica, 12 parts of curculigo orchioides, 12 parts of epimedium herb, 15 parts of peach kernel, 9 parts of salvia miltiorrhiza, 9 parts of scutellaria baicalensis, 15 parts of dipsacus root and 6 parts of raw liquorice. The invention also provides application of the traditional Chinese medicine composition. The invention takes the key pathogenesis of lung impediment, namely heat toxin stasis and obstruction of lung collaterals as the principle, has compact medication and precise and appropriate compatibility of medicines, strengthens body resistance to eliminate pathogenic factors, strengthens the foundation and clears the source. The invention can delay the decline of the lung function of a patient when being applied to clinic. In terms of FVC drop rate: the total effective rate of the Chinese and western medicine combination group is 51.52 percent, which is higher than that of a control group of single-use western medicine (pirfenidone) by 36.36 percent (P is less than 0.05); animal experiments prove that the invention can reduce the lung coefficient of a bleomycin filming rat, the fibrosis condition of a lung pathological section and the levels of KL-6, IL-21 and TGF-beta 1 of the rat. The invention proves that the traditional Chinese medicine composition has a certain improvement effect on pulmonary fibrosis.
A recombinant human bile salt-stimulated lipase (BSSL) that is at least 5% glycosylated is produced by a transgenic non-human animal.   A transgenic sheep whose germ cells and somatic cells contain a recombinant nucleotide molecule at an embryonic stage is described.  The recombinant nucleotide molecule comprises a nucleotide sequence encoding for the BSSL operatively linked to a promoter.  Also described is a process to produce the transgenic sheep and for the production of BSSL. The BSSL is useful in the improvement of the utilization of dietary lipids in preterm born infants and for pathological conditions related to exocrine pancreatic insufficiency.  The condition may be caused by cystic fibrosis.
Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
THIOLA EC (tiopronin) delayed-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N‑(2‑Mercaptopropionyl) glycine and has the following structure:

Tiopronin has the empirical formula C 5H 9NO 3S and a molecular weight of 163.20. In this drug product tiopronin exists as a dl racemic mixture. 

Tiopronin is a white crystalline powder, which is freely soluble in water.

Each THIOLA EC tablet contains 100 or 300 mg of tiopronin. The inactive ingredients in THIOLA EC tablets include lactose monohydrate, hydroxypropyl cellulose, hydroxypropyl cellulose (low substitute), magnesium stearate, hydroxypropyl methylcellulose E5, methacrylic acid: ethyl acrylate copolymer (Eudragit L 100-55), talc, triethyl citrate.